Cargando…
Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity
Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and the main cause of anticoagulation, being direct oral anticoagulants (DOAC) increasingly used in this context. On the other hand, obesity is a known risk thromboembolic factor. In the clinical trials that led to the approval of D...
Autores principales: | Navarro-Almenzar, Begoña, Cerezo-Manchado, Juan José, García-Candel, Faustino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603013/ https://www.ncbi.nlm.nih.gov/pubmed/34825048 http://dx.doi.org/10.1016/j.ijcha.2021.100913 |
Ejemplares similares
-
Direct Oral Anticoagulants in Patients With Cancer and Nonvalvular Atrial Fibrillation
por: Davis, Margot K., et al.
Publicado: (2021) -
Decision of Anticoagulation in Nonvalvular Atrial Fibrillation in the Real World in the Non-Antivitamin K Anticoagulants Era
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2022) -
Physician's Fear of Anticoagulant Therapy in Nonvalvular Atrial Fibrillation
por: Sen, Souvik, et al.
Publicado: (2014) -
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation
por: Schaefer, Jordan K., et al.
Publicado: (2015) -
Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy
por: Ferro, D., et al.
Publicado: (2007)